MedTrace Logo

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

NCT06994676 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-03-16

No results posted yet for this study

Summary

Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will continue CBX-250 until progressive disease (PD) or unacceptable toxicity. All subsequent treatment cycles will be 28 days.

Conditions

  • High-risk Myelodysplastic Syndrome
  • Chronic Myelomonocytic Leukemia (CMML)
  • AML - Acute Myeloid Leukemia
  • Chronic Myeloid Leukemia

Interventions

DRUG

CBX-250

subcutaneous CBX-250

Sponsors & Collaborators

  • Crossbow Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Briggs Morrison, MD · Crossbow Therapeutics, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-16
Primary Completion
2027-01-31
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06994676 on ClinicalTrials.gov